insights_auto
Outlook: 81.0% bullish·0.0% bearish
Go to analysischevron_right
A1ZN34:BVMF
Astrazeneca Plc Bdr
137,77 R$
arrow_downward
-0,07%(-0,100) 1D
2 հոկ, 11:32:23 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1ZN34...
Open
137,43 R$
High
137,84 R$
Low
137,43 R$
Mkt. cap
244,82 մլրդ
Avg. vol.
481,00
Volume
57,00
52-wk high
190,40 R$
52-wk low
130,06 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
Open
137,43 R$
High
137,84 R$
Low
137,43 R$
Mkt. cap
244,82 մլրդ
Avg. vol.
481,00
Volume
57,00
52-wk high
190,40 R$
52-wk low
130,06 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
News stories
From web sources and news partners
The Business Journals
·
32 րոպե առաջ
Innovation roundup: Carnegie Mellon in Miami, AstraZeneca's $2B investment
Yahoo Finance
·
1 ժամ առաջ
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Pharmaceutical Executive
·
1 ժամ առաջ
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
Stock Titan
·
8 ժամ առաջ
AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96,1 հզր
Founded06 ապր, 1999 թ.
HeadquartersՔեմբրիջ, Cambridgeshire, Միացյալ Թագավորություն
Sector-
Websiteastrazeneca.com